4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age50+
Sponsor4D Molecular Therapeutics
About this trial
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.
Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
Eligibility criteria
Qualifiers
50 years of age
≥50 years of age
Diagnosed with CNV secondary to AMD (confirmed by reading center)
Study eye amenable to IVT injection
Disqualifiers
None
Trial design
Treatments tested in this trial
- 4D-150 IVT
- Aflibercept IVT
Treatment groups
215 Participants
are divided into 10 treatment groups10
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov